Covid-19 vaccine effectiveness affected by variants

GlobalData Healthcare 3 March 2021 (Last Updated March 3rd, 2021 16:43)

The effectiveness of COVID-19 vaccinations is being impacted by the emergence of SARS-CoV-2 variants. This could become more problematic as the virus continues to spread, increasing its chance to mutate. These variants could affect not only the effectiveness of the vaccines, but also the natural immunity that COVID-19 survivors have developed, making annual booster shots required for COVID-19 immunity.

Covid-19 vaccine effectiveness affected by variants
Credit: Viacheslav Lopatin/Shutterstock.com

The effectiveness of COVID-19 vaccinations is being impacted by the emergence of SARS-CoV-2 variants. This could become more problematic as the virus continues to spread, increasing its chance to mutate. These variants could affect not only the effectiveness of the vaccines, but also the natural immunity that COVID-19 survivors have developed, making annual booster shots required for COVID-19 immunity.

Several natural variants have been identified, including the B.1.1.7 variant first identified in the UK, the B.1.351 variant first identified in South Africa, and the P.1 variant first identified in Brazil. The B.1.1.7 variant is currently thought to be about 50% more transmissible than the original SARS-CoV-2 strain, and possibly more deadly. However, there is no indication that B.1.1.7 reduces the effectiveness of Moderna or Pfizer COVID-19 vaccines. This is supported by the fact that the B.1.1.7 variant is neutralized by the sera of Pfizer and Moderna vaccine recipients. Still, there is some laboratory evidence of reduced neutralization of the B.1.1.7 variant by convalescent plasma of COVID-19 patients. Novavax reported that its vaccine had 85% efficacy with the variant versus 89% with the non-variant strain, and AstraZeneca/Oxford reported that their vaccine 74% efficacy with the variant versus 84% with the non-variant strain.

The B.1.351 variant is potentially more troubling. Clinical trials for the Pfizer and Moderna vaccines indicate a reduction in sera neutralization of the B.1.351 variant, and other studies have shown there could be a six-fold to 10-fold lower binding affinity for antibodies to the variant. Additionally, Johnson & Johnson’s vaccine had 57% efficacy in South Africa, where the variant is prevalent, versus 72% in the US, and Novavax’s vaccine had 49% efficacy in South Africa versus 90% in the UK. However, World Health Organization director Kate O’Brien indicated that these results may have some uncertainty as they were based on a low number of cases in South Africa. The B.1.351 variant may have a higher chance of reinfecting people who were infected by earlier strains of the SARS-CoV-2 virus.

The P.1 variant has some of the same mutations as the B.1.351 variant and could have a higher chance of reinfecting people. More research needs to be conducted on this variant to monitor its effects.

Pfizer and Moderna are already working on developing booster shots for their vaccines to improve their effectiveness against the B.1.351 strain. As there is already some indication of COVID-19 reinfections and possible waning immunity from naturally recovered COVID-19 patients, yearly boosters may be required for COVID-19. However, it is important to note that despite the presence of these variants in the population, the vaccines are still likely to prevent severe outcomes such as hospitalization and death.

As such, naturally recovered COVID-19 patients should also consider getting vaccinated. Those who have a weak level of response to COVID-19 infection may have a shorter duration of immunity and weaker protection from reinfection. Vaccines can offer a more consistent level of protection and a more robust immune response of neutralizing antibodies. Single-dose boosters provided to patients who have naturally recovered from COVID-19 could increase and extend the duration of their immune response.